Proteomics

Dataset Information

0

Fusion partners influence cellular and molecular phenotypes of oncogenic BRAF fusions


ABSTRACT: Fusion genes can be oncogenic drivers in a variety of cancer types and represent potential targets for targeted therapy. The BRAF gene is frequently involved in oncogenic fusions, with fusion frequencies of 0.2-3% throughout different cancers. However, BRAF fusions rarely occur in the same gene configuration, potentially challenging personalized therapy design. In particular, the influence that is imposed by the wide variety of fusion partners on the oncogenic role of BRAF during tumor growth and drug response is unknown. Here, we used patient-derived colorectal cancer organoids to functionally characterize and cross-compare previously identified BRAF fusions containing various partner genes (AGAP3, DLG1 and TRIM24) with respect to cellular behaviour, downstream signaling activation and response to targeted therapies. We demonstrate that 5’ partner choice of BRAF fusions affects their subcellular localization and intracellular signaling capacity. In particular the DLG1-BRAF fusion protein showed distinct localization to the plasma membrane and exhibited increased activation of downstream MAPK signaling under unperturbed conditions. Moreover, phosphoproteomics and RNA sequencing identified distinct subsets of affected signaling pathways and altered gene expression of BRAF fusions. The different BRAF fusions exhibited varying sensitivities to simultaneous targeted inhibition of MEK and the EGF receptor family. However, all BRAF fusions conveyed resistance to targeted monotherapy against the EGF receptor family, suggesting that BRAF fusions should be screened alongside other MAPK pathway alterations to identify mCRC patients to exclude from cetuximab treatment

INSTRUMENT(S): Orbitrap Fusion

ORGANISM(S): Homo sapiens  

TISSUE(S): Tissue Not Applicable To Dataset

DISEASE(S): Colorectal Cancer

SUBMITTER: Harmjan Vos  

LAB HEAD: Hugo Snippert

PROVIDER: PXD013461 | Pride | 2020-01-16

REPOSITORIES: pride

altmetric image

Publications

Diverse BRAF Gene Fusions Confer Resistance to EGFR-Targeted Therapy via Differential Modulation of BRAF Activity.

Stangl Christina C   Post Jasmin B JB   van Roosmalen Markus J MJ   Hami Nizar N   Verlaan-Klink Ingrid I   Vos Harmjan R HR   van Es Robert M RM   Koudijs Marco J MJ   Voest Emile E EE   Snippert Hugo J G HJG   Kloosterman W P WP  

Molecular cancer research : MCR 20200107 4


Fusion genes can be oncogenic drivers in a variety of cancer types and represent potential targets for targeted therapy. The BRAF gene is frequently involved in oncogenic gene fusions, with fusion frequencies of 0.2%-3% throughout different cancers. However, BRAF fusions rarely occur in the same gene configuration, potentially challenging personalized therapy design. In particular, the impact of the wide variety of fusion partners on the oncogenic role of BRAF during tumor growth and drug respon  ...[more]

Similar Datasets

| EGAS00001003558 | EGA
2013-10-25 | E-GEOD-48850 | ArrayExpress
| GSE111200 | GEO
2019-05-14 | E-GEOD-48850 | ExpressionAtlas
2019-03-22 | E-MTAB-7490 | ArrayExpress
| GSE111320 | GEO
| EGAS00001002149 | EGA
| GSE67841 | GEO
| GSE94464 | GEO
2020-04-02 | PXD016739 | Pride